Gluck Biosciences Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
- Paid Up Capital ₹ 0.10 M
- Company Age 4 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 3.00 Cr
- Revenue Growth %
- Profit Growth 631.02%
- Net Worth 1.57%
- Total Assets 39.49%
About Gluck Biosciences
Gluck Biosciences Private Limited (GBPL) is a Private Limited Indian Non-Government Company incorporated in India on 20 April 2020 (Four years and nine months 22 days old ). Its registered office is in Haridwar, Uttarakhand, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹3.00 Cr.
Om Gupta, Ashish Kesari, and Lilawati Devi serve as directors at the Company.
Company Details
-
Location
Haridwar, Uttarakhand, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24230UR2020PTC010922
-
Company No.
010922
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
20 Apr 2020
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Uttarakhand
Industry
Who are the key members and board of directors at Gluck Biosciences?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Om Gupta
|
Director | 20-Apr-2020 | Current |
|
Ashish Kesari
|
Director | 20-Apr-2020 | Current |
|
Lilawati Devi
|
Director | 21-Jun-2022 | Current |
Financial Performance of Gluck Biosciences.
Gluck Biosciences Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 631.02% increase in profit. The company's net worth moved up by a moderate rise of 1.57%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Gluck Biosciences?
Unlock access to Gluck Biosciences's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
-
Map Pharmaceuticals Private LimitedOm Gupta and Ashish Kesari are mutual person
Charges (Loans)
₹30.00 M
₹0
Charges Breakdown by Lending Institutions
- Others : 3.00 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 26 Dec 2023 | Others | ₹3.00 Cr | Open |
How Many Employees Work at Gluck Biosciences?
Gluck Biosciences has a workforce of 0 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Gluck Biosciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Gluck Biosciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.